Elly Gerald Stoica

Array ( [id] => 11604103 [patent_doc_number] => 20170121404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'BLOCKADE OF RGMb FOR REDUCING TRANSPLANTATION-ASSOCIATED IMMUNE RESPONSES' [patent_app_type] => utility [patent_app_number] => 15/343085 [patent_app_country] => US [patent_app_date] => 2016-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 13862 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15343085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627295 [patent_doc_number] => 20170137484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'METHODS AND COMPOSITIONS FOR CANCER THERAPY USING MUTANT LIGHT MOLECULES WITH INCREASED AFFINITY TO RECEPTORS' [patent_app_type] => utility [patent_app_number] => 15/341678 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 17201 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15341678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522075 [patent_doc_number] => 20180312580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => TRANSFORMING GROWTH FACTOR-BETA-RESPONSIVE POLYPEPTIDES AND THEIR METHODS FOR USE [patent_app_type] => utility [patent_app_number] => 15/772403 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043471 [patent_doc_number] => 20190077842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => Method For Producing A Recombinant Protein With Reduced Impurities [patent_app_type] => utility [patent_app_number] => 15/767246 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314211 [patent_doc_number] => 20180208642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TARGETING PEPTIDE-ELASTIN FUSION POLYPEPTIDES AND THEIR SELF-ASSEMBLED NANOSTRUCTURES [patent_app_type] => utility [patent_app_number] => 15/744278 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14018975 [patent_doc_number] => 20190071481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => Improved Coding Sequence For Human G-CSF [patent_app_type] => utility [patent_app_number] => 15/767221 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542639 [patent_doc_number] => 20170096463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'Modified FGF-21 Polypeptides and Their Uses' [patent_app_type] => utility [patent_app_number] => 15/292700 [patent_app_country] => US [patent_app_date] => 2016-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 115014 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15292700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986567 [patent_doc_number] => 20190062441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies [patent_app_type] => utility [patent_app_number] => 15/766821 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12346908 [patent_doc_number] => 09951139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285120 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18012 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13013931 [patent_doc_number] => 10030073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285183 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18026 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12346908 [patent_doc_number] => 09951139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285120 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18012 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13013931 [patent_doc_number] => 10030073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285183 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18026 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12346908 [patent_doc_number] => 09951139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285120 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18012 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13013931 [patent_doc_number] => 10030073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285183 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18026 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12346908 [patent_doc_number] => 09951139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285120 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18012 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13013931 [patent_doc_number] => 10030073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => Antibodies against human CSF-1R and uses thereof [patent_app_type] => utility [patent_app_number] => 15/285183 [patent_app_country] => US [patent_app_date] => 2016-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18026 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11528632 [patent_doc_number] => 20170088609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'ANTICANCER COMBINATION THERAPY' [patent_app_type] => utility [patent_app_number] => 15/276869 [patent_app_country] => US [patent_app_date] => 2016-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15276869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12983677 [patent_doc_number] => 20170343553 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-11-30 [patent_title] => CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS [patent_app_type] => utility [patent_app_number] => 15/272870 [patent_app_country] => US [patent_app_date] => 2016-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15272870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12983677 [patent_doc_number] => 20170343553 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-11-30 [patent_title] => CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS [patent_app_type] => utility [patent_app_number] => 15/272870 [patent_app_country] => US [patent_app_date] => 2016-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15272870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491497 [patent_doc_number] => 20170065680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'AGENT FOR THE TREATMENT OF ALOPECIA' [patent_app_type] => utility [patent_app_number] => 15/270350 [patent_app_country] => US [patent_app_date] => 2016-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 64451 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15270350 [rel_patent_id] =>[rel_patent_doc_number] =>)